CAR T Cell Therapy
10
4
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (10)
A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products
MB-CART2019.1 in Refractory Multiple Sclerosis
Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia
CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma
Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond
DALY II Japan/MB-CART2019.1 for DLBCL
Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy
Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE